CDM Workshop, Part 1

OHDSI Community Call
March 8, 2022 • 11 am ET
<table>
<thead>
<tr>
<th>Date</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>March 15</td>
<td>CDM Workshop (Part 2)</td>
</tr>
<tr>
<td>March 22</td>
<td>OHDSI Vocabulary Journey</td>
</tr>
<tr>
<td>March 29</td>
<td>Reproducibility</td>
</tr>
<tr>
<td>April 5</td>
<td>Name That Result</td>
</tr>
<tr>
<td>April 12</td>
<td>OHDSI Coordinating Center</td>
</tr>
<tr>
<td>April 19</td>
<td>DARWIN EU</td>
</tr>
<tr>
<td>April 26</td>
<td>Open-Source Community</td>
</tr>
</tbody>
</table>
### Future OHDSI Community Calls

<table>
<thead>
<tr>
<th>Date</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>March 15</td>
<td>CDM Workshop (Part 2)</td>
</tr>
<tr>
<td>March 22</td>
<td>OHDSI Vocabulary Journey</td>
</tr>
<tr>
<td>March 29</td>
<td>Reproducibility</td>
</tr>
<tr>
<td>April 5</td>
<td>Name That Result</td>
</tr>
<tr>
<td>April 12</td>
<td>OHDSI Coordinating Center</td>
</tr>
<tr>
<td>April 19</td>
<td>DARWIN EU</td>
</tr>
<tr>
<td>April 26</td>
<td>Open-Source Community</td>
</tr>
</tbody>
</table>
March 15: CDM Workshop, Part 2

Clair Blacketer
Associate Director
Janssen Research & Development

Anthony Molinaro
Manager, Epidemiology Analytics
Janssen Research & Development

Melanie Philofsky
Senior Business Analyst and Project Manager
Odysseus Data Services, Inc.

Frank DeFalco
Director, Observational Health Data Analytics
Janssen Research & Development
Three Stages of The Journey

Where Have We Been?

Where Are We Now?

Where Are We Going?
Congratulations to the team of Edward Burn, Xintong Li, Kristin Kostka, Henry Morgan Stewart, Christian Reich, Sarah Seager, Talita Duarte-Salles, Sergio Fernandez-Bertolin, María Aragón, Carlen Reyes, Eugenia Martinez-Hernandez, Edelmira Marti, Antonella Delmestri, Katia Verhamme, Peter Rijnbeek, Scott Horban, Daniel Morales, and Daniel Prieto-Alhambra on the study “Background rates of five thrombosis with thrombocytopenia syndromes of special interest for COVID-19 vaccine safety surveillance: Incidence between 2017 and 2019 and patient profiles from 38.6 million people in six European countries” which was recently published in Pharmacoepidemiology and Drug Safety.
Congratulations to the team of Emily Pfaff, Melissa Haendel, Kristin Kostka, Adam Lee, Emily Niehaus, Matvey Palchuk, Kellie Walters, and Christopher Chute on the study “Ensuring a safe(r) harbor: Excising personally identifiable information from structured electronic health record data” which was recently published in the Journal of Clinical and Translational Science.
OHDSI Shoutouts!

Any shoutouts from the community? Please share and help promote and celebrate OHDSI work!

Have a study published? Please send to sachson@ohdsi.org so we can share during this call and on our social channels.
Let’s work together to promote the collaborative work happening in OHDSI!
Three Stages of The Journey

Where Have We Been?
Where Are We Now?
Where Are We Going?
The 2022 OHDSI U.S. Symposium will be held Oct. 14-16 at the Bethesda North Marriott Hotel & Conference Center in Bethesda, Md. The main symposium day is scheduled to be Friday the 14th, while activities will be held the next two days.
# Upcoming Workgroup Calls

<table>
<thead>
<tr>
<th>Date</th>
<th>Time (ET)</th>
<th>Meeting</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tuesday</td>
<td>12 pm</td>
<td>Common Data Model Vocabulary Subgroup</td>
</tr>
<tr>
<td>Wednesday</td>
<td>12 pm</td>
<td>FHIR and OMOP Terminologies Subgroup (Zoom)</td>
</tr>
<tr>
<td>Wednesday</td>
<td>2 pm</td>
<td>Natural Language Processing</td>
</tr>
<tr>
<td>Wednesday</td>
<td>7 pm</td>
<td>Medical Imaging</td>
</tr>
<tr>
<td>Thursday</td>
<td>10 am</td>
<td>Data Quality Dashboard Development</td>
</tr>
<tr>
<td>Thursday</td>
<td>1 pm</td>
<td>OMOP CDM Oncology Vocabulary Subgroup</td>
</tr>
<tr>
<td>Friday</td>
<td>10 am</td>
<td>Phenotype Development and Evaluation</td>
</tr>
<tr>
<td>Friday</td>
<td>11 pm</td>
<td>China Chapter (meeting does not take place in Teams)</td>
</tr>
<tr>
<td>Monday</td>
<td>8 am</td>
<td>Early-Stage Researchers</td>
</tr>
<tr>
<td>Monday</td>
<td>10 am</td>
<td>Healthcare Systems Special Interest Group</td>
</tr>
</tbody>
</table>

[www.ohdsi.org/upcoming-working-group-calls](www.ohdsi.org/upcoming-working-group-calls)
Get Access To Different Teams/WGs/Chapters

The 2021 OHDSI Symposium

The 2021 OHDSI Global Symposium featured plenary presentations on OHDSI’s Impact on the COVID-19 Pandemic, as well as on the Journey to Reliable Evidence. The main days included the State of the Community Presentation, the Collaborator Showcase, and a memorable Closing Ceremony that focused on OHDSI’s work through the perspective of a patient.

There were also a pair of full-day activities, including the OHDSI Summer School.

5. Select the workgroups you want to join (you can refer to the WIKI for work group objectives

   - ATLAS
   - Clinical Trials
   - Common Data Model
   - Data Quality Dashboard Development
   - Early-stage Researchers
   - Education Work Group
   - FHIRE and OMOP
   - Geographic Information System (GIS)
   - HADES Health Analytics Data-to-Evidence Suite
   - Healthcare Systems Interest Group (formerly EHR)
   - Health Equity
   - Latin America
   - Medical Devices
   - Medical Imaging
   - Natural Language Processing
   - OHDSI APAC
   - OHDSI APAC Steering Committee
   - OHDSI Steering Committee
   - Oncology
   - Open-source Community
   - Phenotype Development and Evaluation
   - Population-Level Effect Estimation / Patient-Level Prediction

   - Psychiatry
   - Registry (formerly UK Biobank)
   - Surgery and Perioperative Medicine
   - Vaccine Evidence
   - Vaccine Vocabulary

6. Select the chapter(s) you want to join

   - Africa
   - Australia
   - China
   - Europe
   - Japan
   - Korea
   - Singapore
   - Taiwan

7. Select the studies you want to join

   - HEM-A Health Equity Research Assessment
   - PIONEER for Prostate Cancer (study-a-thon ended)
   - SCYLLA (SARS-CoV-2 Large-scale Longitudinal Analysis)
Get Access To Different Teams/WGs/Chapters

5. Select the workgroups you want to join (you can refer to the WIKI for work group objectives

- ATLAS
- Clinical Trials
- Common Data Model
- Data Quality Dashboard Development
- Early-stage Researchers
- Education Work Group
- BHEM and OMOP
- Geographic Information System (GIS)
- HADES Health Analytics Data-to-Evidence Suite
- Healthcare Systems Interest Group (formerly EHR)
- Health Equity
- Latin America
- Medical Devices
- Medical Imaging
- Natural Language Processing
- OHDSI APAC
- OHDSI APAC Steering Committee
- OHDSI Steering Committee
- Oncology
- Open-source Community
- Phenotype Development and Evaluation
- Population-Level Effect Estimation / Patient-Level Prediction

6. Select the chapter(s) you want to join
- Africa
- Australia
- China
- Europe
- Japan
- Korea
- Singapore
- Taiwan

7. Select the studies you want to join
- HERA—Health Equity Research Assessment
- PIONEER for Prostate Cancer (study-a-then-ended)
- SCYLLA (SARS-CoV-2 Large-scale Longitudinal Analysis)
Latest OHDSI Newsletter Is Available

Community Updates

Where Have We Been

• The community engaged in the Phenotype Phebruary initiative, with 15 different collaborators leading 28 conversations about phenotypes. While the calendar has turned, the value in continuing these conversations remains. You can find all threads on developing and evaluating these phenotypes later in the newsletter.

• Leads from most OHDSI workgroups convened for a leadership summit in early February to highlight 2022 Objectives and Key Results (OKRs), and also discuss best practices for leading their respective teams. To learn more and see the 2022 OKRs, please visit our new workgroups page.

Where Are We Now

• The OHDSI community will work with the Erasmus Medical Center to set up the coordinating center for the new DARWIN EU initiative, which was developed by the European Medicines Agency. Read more about this initiative in the newsletter.

• Clair Blacketer will lead a two-part CDM 5.4 workshop during our March 8 and 15 community calls. Check out the full March schedule later in this newsletter.

Where Are We Going

• The 2022 OHDSI Symposium will be held Oct. 14-16, with the main symposium set for Friday, Oct. 14. More details should be available shortly, but please save those dates.

• The new Open-Source Community Workgroup will host a Developer Conference (DevCon) on Friday, April 22, with plans for several workshops and discussions around new projects and new methods. More information, including how to submit abstracts, will be shared on community calls and our social platforms in March.

The Journey Newsletter (March 2022)

The OHDSI community came together for “Phenotype Phebruary” to both develop and evaluate phenotypes for health outcomes that could be investigated by the community. We reflect on that effort, the recent European Medicines Agency announcement of the DARWIN EU Coordination Center — and how OHDSI fits in that initiative — and discuss plenty more that happened in the community in the latest edition of The Journey! #JoinTheJourney

28 Days, 28 Phenotypes

Phenotype Phebruary

Forums.ohdsi.org

Join The Conversations!

“Phenotype Phebruary” was a community-wide initiative to both develop and evaluate phenotypes for health outcomes that could be investigated by the community. We were so proud to have 15 different members of the community step up and lead forum discussions on phenotypes ranging from Type 2 Diabetes Mellitus to Hypertension to Depression and Delirium.

Check out all the different phenotypes investigated by our community below, visit our Phenotype Phebruary homepage or any of the individual threads, and then add your insights or learn from the great research done by our leads.

Publications


March Update Videocast

Patrick Ryan and Craig Sashin discuss why “Phenotype Phebruary” was such a positive community activity, and how it can help OHDSI research initiatives in the future. They also discuss the recent EMA decision to award OHDSI collaborator Erasmus MC with the DARWIN EU contract, and they reflect on the recent Workgroup Leadership Summit.

@OHDSI

www.ohdsi.org

#JoinTheJourney
Welcome to OHDSI!

The Observational Health Data Sciences and Informatics (or OHDSI, pronounced “Odyssey”) program is a multi-stakeholder, interdisciplinary collaborative to bring out the value of health data through large-scale analytics. All our solutions are open-source.

2021 OHDSI Symposium

The 2021 OHDSI Global Symposium featured plenary presentations on OHDSI’s Impact on the COVID-19 Pandemic, as well as on the Journey to Reliable Evidence. The main days included the State of the Community Presentation, the Collaborator Showcase, and a memorable Closing Ceremony that focused on OHDSI's

To subscribe to the latest OHDSI newsletter, visit ohdssi.org/subscribe-to-our-newsletter.
Latest OHDSI Newsletter Is Available

Please check out our latest Collaborator Spotlight, which features Maxim Moinat.

Learn more about this 2021 Titan Award winner, including how track & field helped lead him to work with health data, his work with open-source tools, the Registry WG, DARWIN EU and more!

The OHDSI community has always been very welcoming. This is such an ambitious group of skilled people, who always try to make time to guide newcomers; it is remarkable. Personally, I have grown to love the field of observational health research.

[ohdsi.org/spotlight-maxim-moinat]
Next CBER Best Seminar

Topic
CBER BEST Seminar Series - Addressing Selection and Confounding Bias in Test-Negative Study Designs for Flu and COVID-19 Monitoring

Description: The test-negative design (TND) has become a standard approach to evaluate vaccine effectiveness against the risk of acquiring infectious diseases such as Influenza, Rotavirus, Dengue fever and more recently COVID-19 in real world settings. Despite the TND's potential to reduce unobserved differences in healthcare seeking behavior (HSB) between vaccinated and unvaccinated subjects, substantial variability in unobserved HSB may remain among study participants. As latent HSB is likely also a strong predictor of selection into the TND sample, confounding bias of the vaccine's causal effect by latent HSB may be induced by collider stratification bias resulting from the TND.

Speakers

Dr. Eric Tchetgen Tchetgen
Lundy Family President’s Distinguished Professor @ Wharton School of the University of Pennsylvania

Eric J. Tchetgen Tchetgen is the Lundy Family President’s Distinguished Professor at the Wharton School of the University of Pennsylvania. Professor Tchetgen Tchetgen comes to the University of Pennsylvania from Harvard University, where he has served since 2008 as Professor of Biostatistics and Epidemiologic Methods with joint appointments in the departments of Biostatistics and Epidemiology at the T.H. Chan School of Public Health. He researches infectious diseases, including HIV/AIDS, and the role of genetic and social factors in the patterns, causes, and effects of public health.

Professor Tchetgen Tchetgen has received grants from the National Institutes of Health and the Centers for Disease Control. He completed his Ph.D. in Biostatistics at Harvard University in 2006 under the supervision of Professor James M. Robins. He received his B.S. in Electrical Engineering from Yale University in 1999.

Wed., April 27, 11 am ET
Speaker: Dr. Nicole Pratt  
Professor, University of South Australia

Description: As recently approved COVID-19 vaccines are rolled out globally, safety signals will be identified from spontaneous reports and other data sources. Although some work has been done to assess the validity of methods for vaccine safety surveillance, discussion remains on the best way to perform analyses in real-world data to ensure rigorous and rapid identification of safety signals. In this talk, we will discuss the “Evaluating Use of Methods for Adverse Event Under Surveillance (for vaccines) (EUMEAU)” task force and its findings on the comparative performance of different analytical methods for the assessment of comparative vaccine safety. We will discuss our findings to-date describing our evaluation of different surveillance methods (historic rate, cohort, self-controlled, etc).

Feb 23, 2022 11:00 AM in Eastern Time (US and Canada)

Speakers

Dr. Nicole Pratt  
Deputy Director of the Quality Use of Medicines and Pharmacy Research Centre @University of South Australia

Dr. Nicole Pratt is the Deputy Director of the Quality Use of Medicines and Pharmacy Research Centre, University of South Australia. She is a member of the Drug Utilisation Subcommittee (DUSC) of the Australian Department of Health Pharmaceutical Benefits Advisory Committee (PBAC). She has a particular interest in new statistical methodologies to study the effectiveness and safety of medicine use and in the development of tools for post-marketing surveillance of medicines. Nicole leads the evaluation of the Department of Veterans Affairs, Veterans’ Medicines Advice and Therapeutics Education Service (Veterans’ MATES) program which uses administrative claims data to develop and evaluate interventions to improve use of medicines in the veteran population in Australia. She was a chief investigator of an NHMRC Centre of Research Excellence in post-market surveillance of medicines and medical devices.
Where Are We Going?

Any other announcements of upcoming work, events, deadlines, etc?
Welcome To OHDSI Newcomers

Are there any new people to the OHDSI community call who would like to introduce themselves?

Please raise your hand and share why you are interested in joining the OHDSI community.
Three Stages of The Journey

Where Have We Been?
Where Are We Now?
Where Are We Going?
Today’s Focus: CDM Workshop, Part 1

Clair Blacketer
Associate Director
Janssen Research & Development

Kristin Kostka
Director of the OHDSI Center
Roux Institute, Northeastern University

Frank DeFalco
Director, Observational Health Data Analytics
Janssen Research & Development

Maxim Moinat
Data Engineer/Software Developer
The Hyve
Dev Con, OHDSI Dashboard

Paul Nagy
Program Director for Graduate Training in Biomedical Informatics and Data Science, Deputy Director of the Johns Hopkins Medicine Technology Innovation Center